GSA Capital Partners LLP Purchases 114,068 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Key Points

• GSA Capital Partners LLP increased its stake in BioCryst Pharmaceuticals by 69.3% during the first quarter, acquiring an additional 114,068 shares, bringing its total to 278,552 shares valued at approximately $2.09 million.
• Analysts are optimistic about BioCryst Pharmaceuticals, with average ratings of "Buy" and target prices ranging from $10.00 to $30.00, suggesting significant potential for growth.
• The current share price of BioCryst Pharmaceuticals is approximately $8.26, with a market cap of $1.73 billion and a 52-week high of $11.31.

GSA Capital Partners LLP grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 69.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 278,552 shares of the biotechnology company's stock after purchasing an additional 114,068 shares during the period. GSA Capital Partners LLP owned approximately 0.13% of BioCryst Pharmaceuticals worth $2,089,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of BCRX. Raymond James Financial Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $80,000. Teacher Retirement System of Texas boosted its stake in shares of BioCryst Pharmaceuticals by 25.1% during the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company's stock valued at $438,000 after purchasing an additional 11,711 shares in the last quarter. Sei Investments Co. boosted its stake in shares of BioCryst Pharmaceuticals by 2.8% during the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock valued at $430,000 after purchasing an additional 1,537 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $299,000. Finally, Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the period. Institutional investors own 85.88% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Royal Bank Of Canada reissued an "outperform" rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. JPMorgan Chase & Co. lifted their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $8.26 on Tuesday. The firm has a fifty day moving average price of $9.72 and a 200 day moving average price of $8.72. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $11.31. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -31.77, a P/E/G ratio of 1.40 and a beta of 1.04.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.